Avanir Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $53.3M | 5,827 | 78.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8.5M | 5,017 | 12.6% |
| Food and Beverage | $3.1M | 155,299 | 4.6% |
| Consulting Fee | $1.6M | 382 | 2.4% |
| Travel and Lodging | $1.1M | 3,850 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $134,700 | 96 | 0.2% |
| Education | $6,543 | 716 | 0.0% |
| Gift | $4,377 | 3 | 0.0% |
| Charitable Contribution | $2,800 | 2 | 0.0% |
| Grant | $2,500 | 2 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 15-AVP-786-303 | $12.9M | 3 | 1,457 |
| 15-AVP-786-302 | $7.8M | 3 | 712 |
| 15-AVP-786-301 | $5.5M | 5 | 623 |
| 17-AVP-786-205 | $3.1M | 1 | 710 |
| 19-AVP-786-112 | $2.4M | 0 | 18 |
| 17-AVP-786-305 | $2.4M | 0 | 398 |
| 18-AVP-786-207 | $2.1M | 1 | 466 |
| 19-AVP-786-111 | $1.8M | 0 | 24 |
| 18-AVP-786-108 | $1.5M | 0 | 24 |
| 17-AVP-825-301 | $1.5M | 2 | 217 |
| 15-786-303 | $1.3M | 0 | 127 |
| 18-AVP-786-107 | $1.2M | 0 | 20 |
| 20-AVP-786-306 | $1.1M | 0 | 277 |
| EfficacySafetyTolerabilityAVP-786ForTreatment AgitationinPatientsW/Dementia of the Alzheimer's Type | $1.1M | 3 | 170 |
| 19-AVP-786-110 | $820,788 | 0 | 10 |
| 17-AVP-786-106 | $696,141 | 0 | 24 |
| 17-AVR-135 | $693,753 | 0 | 33 |
| 15-786-302 | $689,522 | 0 | 64 |
| 19-AVP-786-109 | $687,285 | 0 | 6 |
| 15-AVP-786-202 | $659,747 | 1 | 47 |
| 15-786-301 | $627,761 | 0 | 85 |
| 20-AVP-786-307 | $596,750 | 0 | 176 |
| 19-AVP-786-108 | $557,850 | 0 | 3 |
| 19-AVP-786-108, 19-AVP-786-109, 19-AVP-786-110, 19-AVP-786-111, 19-AVP-786-112, 19-AVP-786-113 | $353,750 | 0 | 1 |
| 17-AVP-786-206 | $272,524 | 0 | 56 |
| Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia | $233,030 | 0 | 18 |
| Rat model of behavioral aspects of traumatic brain | $98,540 | 0 | 2 |
| Prevalence of Pseudobulbar Affect Symptoms in Professional Fighters and association with neurologica | $90,744 | 0 | 1 |
| AVS-P2-028, AVS-P9-189, AVS-P7-303, AVS-P3-114 | $79,250 | 0 | 1 |
| 15-AVP-706-202 | $73,270 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Jason Caplan, Md, MD | Psychosomatic Medicine | Phoenix, AZ | $528,693 | $0 |
| Adam Sky, Md, MD | Psychiatry | Saint Louis, MO | $524,512 | $0 |
| Charles Nevels, Md, MD | Psychiatry | Tuscaloosa, AL | $431,931 | $0 |
| Dr. Kenneth Colley, Md, MD | Internal Medicine | San Francisco, CA | $386,162 | $0 |
| Dr. Syed Asad, M.d, M.D | Nuclear Medicine | Jacksonville, FL | $372,551 | $0 |
| Dr. Amita Patel, M.d, M.D | Psychiatry | Dayton, OH | $347,987 | $0 |
| Dr. Vadim Baram, Md, MD | Geriatric Psychiatry | Saint Louis, MO | $233,928 | $0 |
| Parikshit Deshmukh, M.d, M.D | Psychiatry | Ocala, FL | $224,914 | $0 |
| Dr. Michael Kwiat, Md, MD | Psychiatry | Beaver, PA | $223,900 | $0 |
| Dr. Gustavo Alva, M.d, M.D | Psychiatry | Orange, CA | $198,795 | $0 |
| Dr. Daniel Kantor, M.d, M.D | Neurology | Coconut Creek, FL | $195,248 | $0 |
| Stanley Fisher, M.d, M.D | Neurology | Kansas City, MO | $194,783 | $0 |
| Jeffrey Kittrelle, Md, MD | Clinical Pharmacology | San Diego, CA | $181,227 | $0 |
| Dr. Steven Warren, Md Dpa, MD DPA | Geriatric Medicine | Bountiful, UT | $168,622 | $0 |
| Dr. Steven Fogelman, M.d, M.D | Psychiatry | Rome, NY | $164,771 | $0 |
| Andrew Graf | Internal Medicine | Plymouth Meeting, PA | $159,537 | $0 |
| Elizabeth Coon-Nguyen, Md, MD | Family Medicine | Kingwood, TX | $152,072 | $0 |
| Hari Kannan, M.d, M.D | Psychiatry | Sioux Falls, SD | $147,519 | $0 |
| Dr. John Norton, M.d, M.D | Psychiatry | Jackson, MS | $141,246 | $0 |
| Shervin Mortazavi, M.d, M.D | Internal Medicine | Bronx, NY | $137,222 | $0 |
| Dr. Michelle Dees, Md, MD | Psychiatry | Chicago, IL | $134,299 | $0 |
| Yadagiri Chepuru, Md, MD | Psychiatry | Yonkers, NY | $127,898 | $0 |
| Dr. David Crumpacker, Md, MD | Psychiatry | Plano, TX | $122,428 | $0 |
| Dr. Nathaniel Whaley, Md, MD | Neurology | Johnson City, TN | $119,608 | $0 |
| Matthew Baker, Md, MD | Neurology | Naples, FL | $117,583 | $0 |
Top Products
- NUEDEXTA $10.7M
- ONZETRA Xsail $1.7M
Associated Products (4)
- NUEDEXTA $12.2M
- ONZETRA Xsail $1.7M
- Nuedexta $662,629
- ONZETRA $13,689
Payment Categories
- Food & Beverage $3.1M
- Consulting $1.6M
- Travel & Lodging $1.1M
- Research $53.3M
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. has made $67.8M in payments to 32,877 healthcare providers, recorded across 171,194 transactions in the CMS Open Payments database. In 2022, the company paid $2.5M. The top product by payment volume is NUEDEXTA ($10.7M).
Payments were distributed across 231 medical specialties. The top specialty by payment amount is Psychiatry ($4.5M to 3,474 doctors).
Payment categories include: Food & Beverage ($3.1M), Consulting ($1.6M), Research ($53.3M), Travel & Lodging ($1.1M).
Avanir Pharmaceuticals, Inc. is associated with 4 products in the CMS Open Payments database, including NUEDEXTA, ONZETRA Xsail, and Nuedexta.